J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis

J&J still sees room for plenty of Tremfya growth in a psoriasis market it calls “dramatically underpenetrated” by biologics. (Johnson & Johnson)

SAN FRANCISCO—Johnson & Johnson knows the immunology market is crowded. But that doesn’t mean it doesn’t still see tons of opportunity there.

“We do look at immunology as being very, very attractive, and in certain areas, there’s so much unmet medical need,” Jennifer Taubert, executive vice president and worldwide pharma chairman, said Monday during a fireside chat at the J.P. Morgan Healthcare Conference.

RELATED: Johnson & Johnson's Tremfya gets its go-ahead to fight Novartis, Lilly in psoriasis. Can it stand out?

One of those areas—psoriasis—might surprise investors who have watched Novartis’ Cosentyx, Eli Lilly’s Taltz, Valeant’s Siliq, J&J’s own Tremfya and Sun Pharmaceutical’s Ilumya enter the market over the last few years. But the way Taubert sees it, the market is still “dramatically underpenetrated” by biologics.

And therein lies the opportunity for Tremfya, a drug that’s made big strides despite some big-name competitors that got a head start. “Not only do we have the right product, we’ve actually done the right clinical scientific work to be able to demonstrate” it, Taubert said.

She pointed to a head-to-head superiority study versus AbbVie behemoth Humira, a head-to-head against J&J’s Stelara and, most recently, a head-to-head showdown with Cosentyx that came out in Tremfya’s favor.

RELATED: Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown

“Even though it is relatively speaking a bit more crowded and competitive, there’s still a very compelling value proposition there,” she added.

And that’s not the only area in which J&J sees room for growth. The company would love to eventually play in fields such as lupus and atopic dermatitis, Taubert said. Stelara, which is showing “very strong success” in a new Crohn’s indication, could also move over to ulcerative colitis.

Of course, those arenas boast their own share of tough competitors—Sanofi and Regeneron’s Dupixent, for one, last year won an atopic dermatitis nod, and the product is expected to rake in blockbuster sales. But a little rivalry won’t deter J&J. As long as you have the “right value, the right product and the right data … you can bring that forward very successfully,” Taubert said.

Suggested Articles

Astellas and Seattle Genetics are out with Padcev-Keytruda combo data that may be good enough to snag an expedited regulatory review, analysts say.

Distributors had offered billions of dollars to wrap up opioid litigation, but that effort has suffered a major setback, WSJ reports.

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.